Condensed Statements of Operations - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Revenue		$ 900,000
Operating expenses:
Research and development (in the three months ended March 31, 2022 and 2021, net of collaboration funding of $2,999,371 and $286,103, respectively)	$ 3,171,639	2,005,905
General and administrative (in the three months ended March 31, 2022 and 2021, net of collaboration funding of $2,372,175 and $0, respectively)	3,875,601	3,514,141
Total operating expenses	7,047,240	5,520,046
Loss from operations	(7,047,240)	(4,620,046)
Other (expense) income, net:
Costs of debt issuance	(1,168,065)
Changes in fair value of debt instruments	(962,400)
Interest and other (expense) income, net	(2,838)	(40,163)
Foreign currency transaction gain	1,539	48,904
Total other (expense) income, net	(2,131,764)	8,741
Net loss	$ (9,179,004)	$ (4,611,305)
Net loss per share - basic and diluted	$ (0.64)	$ (0.33)
Weighted average common shares outstanding - basic and diluted	14,310,244	14,139,916